---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026020"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:43:47.852259+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed

## Summary
- 7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.
- No dose-limiting toxicity, ICANS, GvHD, or >Gr3 CRS; safety profile supports outpatient administration.
- Durable responses >6 months seen; 5 CRs after one cycle, 3 partial responses deepened to CR with additional cycles.
- Dose expansion open: monotherapy in LBCL (CAR T naive/experienced) and combination with rituximab.
- Conference call held Dec 5, 2022; NKX019 is an off-the-shelf allogeneic CAR-NK therapy targeting CD19.

## SEC filing metadata
- accession: 0000950170-22-026020
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/0000950170-22-026020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/nktx-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026020
- JSON: https://secwatch.observer/filing/0000950170-22-026020.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.